Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] Journal article | | Title | Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. | | Author(s) | Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, Sereika SM, Vogel VG | | Institution | University of Pittsburgh, Department of Medicine, Magee Womens Hospital/University of Pittsburgh Breast Program, University of Pittsburgh Medical Center Hillman Cancer Center, Departments of Medicine, Biostatistics, Health and Community Systems, Biostatistics, and Epidemiology, University of Pittsburgh, Pittsburgh, PA; and the Department of Medicine, University of Kansas, Kansas City, KS. | | Source | J Clin Oncol 2008 Apr 21. | | Abstract | PURPOSE: Limited data are available on the efficacy of oral bisphosphonate therapy in breast cancer survivors. Our goal was to examine prevention of breast cancer-related bone loss in this cohort.
PATIENTS AND METHODS: Eighty-seven postmenopausal women after chemotherapy for breast cancer were randomly assigned to once-weekly risedronate 35 mg or placebo for 24 months. Outcomes included bone mineral density (BMD) and turnover markers.
RESULTS: At study initiation, 13% of patients were on an aromatase inhibitor (AI). After 24 months, there were differences of 1.6 to 2.5% (P < .05) at the spine and hip BMD between the placebo and risedronate groups. At study completion, 44% were on an AI. Adjusting for an AI, women on placebo plus AI had a decrease in BMD of (mean +/- SE) 4.8% +/- 0.8% at the spine and 2.8% +/- 0.5% at the total hip (both P < .001). In women on risedronate + AI, the spine decreased by 2.4% +/- 1.1% (P < .05) and was stable at the hip. Women in the placebo group not on an AI, maintained BMD at the spine, and had a 1.2% +/- 0.5% loss at the total hip (P < .05). Women who received risedronate but no AI had the greatest improvement in BMD of 2.2% +/- 0.9% (P < .05) at the total hip. Bone turnover was reduced with risedronate. There were no differences in adverse events between the groups.
CONCLUSION: We conclude that in postmenopausal women with breast cancer with or without AI therapy, once-weekly oral risedronate was beneficial for spine and hip BMD, reduced bone turnover, and was well tolerated. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 18427147 |
|
|
| |
Advertise on this site.
| | |
|
